Compare Diageo plc (DEO) vs Summit Therapeutics Inc (SMMT) Price & Performance

Diageo (DEO) trades at $86.98, up 2.66% with bullish technical indicators and strong institutional support. The company demonstrates solid fundamentals with consistent earnings beats, a 15.82% ROE, and improving cash flow trends. Recent corporate developments include a new CFO appointment and marketing initiatives across key brands, while analyst consensus remains positive with 49% buy ratings.

The outlook remains favorable with restructuring savings and brand investments driving potential upside, though investors face risks from US market challenges and regulatory pressures. The stock's current valuation at 27.9x P/E appears reasonable given the company's market leadership and turnaround progress under new management.

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.